Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes   non-small cell lung cancer to radiotherapy

doi:10.1097/CAD.0b013e32834618bc

CORC > 北京大学 > 生命科学学院

	Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy
	Wang, Lei ; Fu, Jia-ning ; Wang, Jing-yu ; Jin, Cun-jing ; Ren, Xiao-yuan ; Tan, Qiang ; Li, Jing ; Yin, Han-wei ; Xiong, Kun ; Wang, Tian-yu ; Liu, Xin-min ; Zeng, Hui-hui
刊名	anti cancer drugs
	2011
关键词	ethaselen NF-kappa B non-small cell lung cancer radiosensitizer thioredoxin reductase inhibitor IONIZING-RADIATION KAPPA-B APOPTOSIS LINES CARBOPLATIN THERAPY GROWTH EXPRESSION MECHANISM
DOI	10.1097/CAD.0b013e32834618bc
英文摘要	It has been proposed that thioredoxin reductase (TR) is a mediator that allows non-small cell lung cancer (NSCLC) to develop resistance to irradiation; however, little is known regarding the detailed mechanisms of action. Thus, ethaselen {1, 2-[bis (1,2-benzisoselenazolone-3 (2H)-ketone)] ethane, BBSKE}, a novel organoselenium TR inhibitor, is currently being investigated in a phase I clinical trial in China. However, its radiosensitizing effect remains unexplored. In this study, we found that the activity of TR increased dramatically in both A549 and H1299 cells after radiation, and moreover, could be inhibited by pretreatment with BBSKE (5 mu mol/l). As a TR inhibitor, BBSKE enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-kappa B activation dramatically when using A549 cells stably transfected with NF-kappa B luciferase reporter. These results show the critical role of TR in the radioresistance of NSCLC and suggest that BBSKE is a potentially promising agent for the treatment of patients with NSCLC clinically. Anti-Cancer Drugs 22:732-740 (C) 2011 Wolters Kluwer Health \| Lippincott Williams & Wilkins.; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000293212800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701 ; Oncology; Pharmacology & Pharmacy; SCI(E); PubMed; 14; ARTICLE; 8; 732-740; 22
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/323077]
专题	生命科学学院
推荐引用方式 GB/T 7714	Wang, Lei,Fu, Jia-ning,Wang, Jing-yu,et al. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy[J]. anti cancer drugs,2011.
APA	Wang, Lei.,Fu, Jia-ning.,Wang, Jing-yu.,Jin, Cun-jing.,Ren, Xiao-yuan.,...&Zeng, Hui-hui.(2011).Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.anti cancer drugs.
MLA	Wang, Lei,et al."Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy".anti cancer drugs (2011).